# Understanding and manipulating programmed cell death (PCD) pathways to facilitate lymphoid tumor killing by CAR T cells

> **NIH NIH R01** · MASSACHUSETTS GENERAL HOSPITAL · 2021 · $720,152

## Abstract

PROJECT SUMMARY
Recent advances using CAR T cells in lymphoid malignancies have made it clear that manipulation of the host
immune system can radically alter the course of a cancer. Although there have been lifesaving responses in
some patients, all too many patients have inadequate responses. Some patients and tumor types have been
more amenable to CAR T cell therapies than others, despite similar levels of antigen expression, uniformity,
and density. The exact mechanisms by which CAR T cells induce tumor cell death are unknown, and may be
due to a combination of multiple T cell effector functions that ultimately result in cell death, potentially by
triggering programmed cell death in tumor cells. Our overall hypothesis is that CAR T cells mediate tumor cell
death by inducing programmed cell death (PCD) pathways in target cells. A logical corollary of this hypothesis
is that one potential mechanism of resistance, which has received scant attention, is genetic or functional
resistance to PCD in the target tumor cells. Furthermore, we hypothesize that the state of PCD constituents in
tumor cells confers sensitivity or resistance to T-cell mediated killing, and that this relative resistance can be
overcome with drugs that enhance PCD signaling in tumor cells. Finally, because systemically administered
drugs that enhance PCD signaling may also affect CAR T cells, we propose genetic engineering approaches to
render CAR T cells resistant to candidate PCD-enhancing drugs. This is a collaborative project between an
expert in CAR T cells and immunology and an expert in programmed cell pathways and tumor biology.
Together we aim to define the effector functions of T cells that induce tumor cell death (Aim 1), define the
programmed cell death pathways in tumors that confer sensitivity or resistance to CAR T cell mediated killing
(Aim 2), and use innovative strategies to enhance CAR T cell killing of tumor cells by manipulating PCD
pathways using small molecule drugs in combination with genetic engineering of the CAR T cells.

## Key facts

- **NIH application ID:** 10120167
- **Project number:** 1R01CA249062-01A1
- **Recipient organization:** MASSACHUSETTS GENERAL HOSPITAL
- **Principal Investigator:** Marcela Valderrama Maus
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $720,152
- **Award type:** 1
- **Project period:** 2021-01-07 → 2025-12-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10120167

## Citation

> US National Institutes of Health, RePORTER application 10120167, Understanding and manipulating programmed cell death (PCD) pathways to facilitate lymphoid tumor killing by CAR T cells (1R01CA249062-01A1). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10120167. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*